同位素
同位素
동위소
ISOTOPES
2001年
2期
122-125
,共4页
甲状腺疾病%TRAb(促甲状腺激素受体抗体)%放射免疫分析法(RIA)
甲狀腺疾病%TRAb(促甲狀腺激素受體抗體)%放射免疫分析法(RIA)
갑상선질병%TRAb(촉갑상선격소수체항체)%방사면역분석법(RIA)
对甲状腺疾病患者(共758例，其中：初诊甲亢组166例，甲亢内科治疗甲功正常组198例，甲亢内科治疗甲功异常组86例，甲亢内科治疗甲减组24例，甲亢131I治疗甲功正常组104例，亚甲炎组48例，单纯性甲状腺肿组52例，原发性甲减组80例)及62例正常人的血清TRAb(促甲状腺激素受体抗体)浓度进行了放免检则。结果表明：初诊甲亢组甲亢内科治疗甲功正常组、甲亢内科治疗甲功异常组、甲亢内科治疗甲减组、甲亢131I治疗甲功正常组、原发性甲减组的血清TRAb明显增高，与正常对照组比较，P<0.01，有显著性差异；亚甲炎组、单纯性甲状腺肿组的血清TRAb正常，与正常对照组比较，P>0.05，无显著性差异。甲亢内科治疗甲功正常组的TRAb均值和阳性率与甲功异常组比较，皆P<0.01，有显著性差异；甲亢内科治疗甲功正常组TRAb均值和阳性率与甲亢131I治疗甲功正常组比较，皆P<0.01，有显著性差异。由此可见，甲亢和原发性甲减患者血清TRAb浓度普遍升高，亚甲炎、单纯性甲状腺肿患者血清TRAb浓度不升高。因此TRAb的放免检测可认为是甲亢、甲减的辅助诊断指标，也是甲亢和亚甲炎的鉴别诊断指标；同时，TRAb是评价机体自身免疫监护功能的重要指标，也是停用甲状腺药物的一项指标。
對甲狀腺疾病患者(共758例，其中：初診甲亢組166例，甲亢內科治療甲功正常組198例，甲亢內科治療甲功異常組86例，甲亢內科治療甲減組24例，甲亢131I治療甲功正常組104例，亞甲炎組48例，單純性甲狀腺腫組52例，原髮性甲減組80例)及62例正常人的血清TRAb(促甲狀腺激素受體抗體)濃度進行瞭放免檢則。結果錶明：初診甲亢組甲亢內科治療甲功正常組、甲亢內科治療甲功異常組、甲亢內科治療甲減組、甲亢131I治療甲功正常組、原髮性甲減組的血清TRAb明顯增高，與正常對照組比較，P<0.01，有顯著性差異；亞甲炎組、單純性甲狀腺腫組的血清TRAb正常，與正常對照組比較，P>0.05，無顯著性差異。甲亢內科治療甲功正常組的TRAb均值和暘性率與甲功異常組比較，皆P<0.01，有顯著性差異；甲亢內科治療甲功正常組TRAb均值和暘性率與甲亢131I治療甲功正常組比較，皆P<0.01，有顯著性差異。由此可見，甲亢和原髮性甲減患者血清TRAb濃度普遍升高，亞甲炎、單純性甲狀腺腫患者血清TRAb濃度不升高。因此TRAb的放免檢測可認為是甲亢、甲減的輔助診斷指標，也是甲亢和亞甲炎的鑒彆診斷指標；同時，TRAb是評價機體自身免疫鑑護功能的重要指標，也是停用甲狀腺藥物的一項指標。
대갑상선질병환자(공758례，기중：초진갑항조166례，갑항내과치료갑공정상조198례，갑항내과치료갑공이상조86례，갑항내과치료갑감조24례，갑항131I치료갑공정상조104례，아갑염조48례，단순성갑상선종조52례，원발성갑감조80례)급62례정상인적혈청TRAb(촉갑상선격소수체항체)농도진행료방면검칙。결과표명：초진갑항조갑항내과치료갑공정상조、갑항내과치료갑공이상조、갑항내과치료갑감조、갑항131I치료갑공정상조、원발성갑감조적혈청TRAb명현증고，여정상대조조비교，P<0.01，유현저성차이；아갑염조、단순성갑상선종조적혈청TRAb정상，여정상대조조비교，P>0.05，무현저성차이。갑항내과치료갑공정상조적TRAb균치화양성솔여갑공이상조비교，개P<0.01，유현저성차이；갑항내과치료갑공정상조TRAb균치화양성솔여갑항131I치료갑공정상조비교，개P<0.01，유현저성차이。유차가견，갑항화원발성갑감환자혈청TRAb농도보편승고，아갑염、단순성갑상선종환자혈청TRAb농도불승고。인차TRAb적방면검측가인위시갑항、갑감적보조진단지표，야시갑항화아갑염적감별진단지표；동시，TRAb시평개궤체자신면역감호공능적중요지표，야시정용갑상선약물적일항지표。
The TRAb content of the thyroid diseases 758 cases (including the first visit thyroidism group 166 cases; the thyroidism group with normal thyroid function by mesicine treatment 198 cases, the group with abnormal thyroid function by medicine treatment 86 cases, the group with lower thyroid function 24 cases, the group with normal thyroid function by 131I treatmnt 104 cases, the subacute thyroiditis group 48 cases, the simple goiter group 52 cases, the primary hypothyroidism group 80 cases) and the normal control group 62 cases are detected. The results show that the values of TRAb are much higher in the groups with normal or abnormal thyroid function by medicine treatment, the group with lower thyroid function, the group with 131I treatment and the group with primary hypothyoidism than that of control group (P<0.01). The values of TRAb are normal in the groups with subacute thyroiditis and simple goiter compared with control group (P>0.05). The differential of the TRAb average and positive rate is obvious between the groups with normal and abnormal thyroid function by medicine treatment (P<0.01), as well as between the groups the normal thyroid function by medicine and 131I treatment (P<0.01). The TRAb levels in serum are higher in the patients with thyroidism and primary hypo-thyroidism, and the TRAb levels are normal in the patients with subacute thyroiditis and simple goiter. So, TRAb is a auxiliary index in the diagnosis of thyroidism and hypo-thyroidism and also a differential diagnosis index about the thyroidism and subacute thyroiditis. At the same time, TRAb is an important index in evaluating the autoimmune monitoring function of the body, and stopping the use of thyroid medicine.
